Search Results

WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announced today the official launch of IRB+, a groundbreaking service that transforms the landscape of Institutional Review Board (IRB) operations.

A BioSpace analysis of all 80 priority review vouchers that have been handed out across the three FDA programs that offer them found that 2024 was the busiest year yet. Companies have disclosed spending $513 million on vouchers that were earned in 2024 so far.

While Congress is renewing the priority review voucher program for rare pediatric diseases, the FDA should be required to keep public records of the passes changing hands, too.

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple effect is already being felt across biopharma.

StimLabs, a leading regenerative medicine company, announced Institutional Review Board (IRB) authorization to begin the CAMPSTIM clinical trial, a multi-center randomized controlled trial to demonstrate the real-world benefits of StimLabs’ placental-based tissue products in treating patients with hard-to-heal diabetic foot ulcers (DFUs).